Sign in
ARAV Stock Price, Chart, Stats & News
Aravive, Inc.
Save
2.95M
Market cap
–
Current P/E
–
Forward P/E
ARAV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -632.60% |
Operating margin | -775.28% |
Pretax margin | -835.31% |
Net margin | -885.64% |
Effective tax rate | -6.03% |
ROA | -130.20% |
ROE | -306.06% |
D/E | 0.59x |
Interest coverage ratio | -15.40x |
ARAV valuation
P/E | – |
P/S | 0.32x |
P/B | 0.14x |
P/CF | -0.02x |
P/FCF | -0.05x |
P/OCF | -0.02x |
PEG | -0.00x |
EV multiple | -0.71x |
About
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma.
Similar securities
Based on sector and market capitalization
Report issue